California court says drugmakers have no duty to innovate

California’s Supreme Court sided with Gilead Sciences on a claim that drugmakers must do more than sell a non-defective medicine, ruling they have no legal duty to innovate. The decision in Gilead Tenofovir Cases, S283862, draws a sharp line between punishing a flawed product and second-guessing a company’s research choices.

Justice Groban authored the majority opinion, with Justices Corrigan, Liu, Kruger and Desautels concurring. Chief Justice Guerrero filed a separate concurring opinion, Justice Kruger wrote another concurrence joined by Justices Corrigan and Desautels, and Justice Evans dissented. The court had taken up the issue after indicating that the question could reshape product liability law if it were used to require drugmakers to spend more to develop and commercialize safer alternatives.

The dispute centered on Gilead’s FDA-approved HIV drug tenofovir disoproxil fumarate, known as TDF, and a newer formulation, tenofovir alafenamide, or TAF. The California Court of Appeal, First Appellate District, Division Four, had previously held in A165558 that if Gilead’s decision to delay development of TAF breached a duty of reasonable care to TDF users, the company could face liability. That theory was rejected at the state’s highest court.

The underlying lawsuits involved more than 24,000 HIV-infected patients, according to a Reuters-linked background account. Gilead’s own litigation materials framed the case as a fight over whether California law could force manufacturers not only to sell non-defective products, but also to research, develop and sell different drugs that some consumers might later prefer for safety or other reasons.

The ruling matters far beyond one company in Foster City and San Francisco. California remains a major biotech and pharmaceutical hub, and the decision will shape how drugmakers, investors and plaintiffs assess the risk of product-liability suits tied to older medicines that are later overtaken by newer formulations. If courts had accepted a duty to innovate, litigation could have reached deeper into research pipelines and imposed pressure on companies to choose one development path over another.

For patients and public-health advocates, the decision means the push for safer next-generation drugs will continue to run through regulation, patents, market competition and scientific development, not a broad common-law obligation. For pharmaceutical companies, it offers reassurance that a court will not easily punish a firm simply for deciding not to commercialize a different drug faster.